Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma has increased its share capital and voting rights following a directed issue of 2,883,725 new shares resolved by the board earlier in March 2026. As a result, the total number of registered shares and votes in the company now stands at 56,213,968, modestly diluting existing shareholders while potentially strengthening the company’s financial capacity to advance its clinical pipeline in inflammatory disease.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation via selective activation of the melanocortin system. Its portfolio comprises oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and pro-resolution activity, aiming to restore immune balance in patients with inflammatory conditions.
Average Trading Volume: 182,633
Technical Sentiment Signal: Sell
Current Market Cap: SEK958.9M
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.